This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v2.0 was used to generate the results found in this report.
-
Working with individual set: READ
-
Number of patients in set: 69
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:READ.final_analysis_set.maf
-
Significantly mutated genes (q ≤ 0.1): 17
-
Mutations seen in COSMIC: 222
-
Significantly mutated genes in COSMIC territory: 10
-
Genes with clustered mutations (≤ 3 aa apart): 117
-
Significantly mutated genesets: 114
-
Significantly mutated genesets: (excluding sig. mutated genes):0
-
Read 38 MAFs of type "Broad"
-
Read 35 MAFs of type "Baylor"
-
Total number of mutations in input MAFs: 29413
-
After removing 257 invalidated mutations: 29156
-
After removing 200 noncoding mutations: 28956
-
After collapsing adjacent/redundant mutations: 21678
-
Number of mutations before filtering: 21678
-
After removing 172 mutations outside gene set: 21506
-
After removing 172 mutations outside category set: 21334
-
After removing 5 "impossible" mutations in
-
gene-patient-category bins of zero coverage: 21329
type | count |
---|---|
De_novo_Start_InFrame | 4 |
De_novo_Start_OutOfFrame | 30 |
Frame_Shift_Del | 153 |
Frame_Shift_Ins | 155 |
In_Frame_Del | 27 |
In_Frame_Ins | 7 |
Missense_Mutation | 14491 |
Nonsense_Mutation | 1780 |
Nonstop_Mutation | 6 |
Read-through | 10 |
Silent | 4633 |
Splice_Site | 38 |
Total | 21334 |
category | n | N | rate | rate_per_mb | relative_rate |
---|---|---|---|---|---|
*CpG->T | 4922 | 112840423 | 0.000044 | 44 | 5.4 |
*Cp(A/C/T)->mut | 6686 | 933772624 | 7.2e-06 | 7.2 | 0.88 |
A->mut | 2744 | 1010264149 | 2.7e-06 | 2.7 | 0.33 |
*CpG->(G/A) | 135 | 112840423 | 1.2e-06 | 1.2 | 0.15 |
indel+null | 2054 | 2056877265 | 1e-06 | 1 | 0.12 |
double_null | 157 | 2056877265 | 7.6e-08 | 0.076 | 0.0094 |
Total | 16698 | 2056877265 | 8.1e-06 | 8.1 | 1 |
The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).
Column Descriptions:
-
N = number of sequenced bases in this gene across the individual set
-
n = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
n1 = number of nonsilent mutations of type: *CpG->T
-
n2 = number of nonsilent mutations of type: *Cp(A/C/T)->mut
-
n3 = number of nonsilent mutations of type: A->mut
-
n4 = number of nonsilent mutations of type: *CpG->(G/A)
-
n5 = number of nonsilent mutations of type: indel+null
-
n6 = number of nonsilent mutations of type: double_null
-
p_classic = p-value for the observed amount of nonsilent mutations being elevated in this gene
-
p_ks = p-value for clustering of mutations (Kolmogorov-Smirnoff test)
-
p_cons = p-value for enrichment of mutations at evolutionarily most-conserved sites in gene
-
p_joint = p-value for clustering + conservation
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_classic | p_ks | p_cons | p_joint | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | APC | adenomatous polyposis coli | 592848 | 66 | 57 | 56 | 0 | 1 | 4 | 4 | 0 | 39 | 18 | <1.00e-15 | 2e-07 | 0.9 | 0.000022 | <0.000 | <0.000 |
2 | TP53 | tumor protein p53 | 89473 | 45 | 45 | 30 | 1 | 19 | 6 | 6 | 2 | 12 | 0 | 3.66e-15 | 2e-07 | 2e-07 | 0 | <1.00e-15 | <4.50e-12 |
3 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 48783 | 38 | 38 | 8 | 0 | 0 | 36 | 1 | 0 | 1 | 0 | 1.89e-15 | 2e-07 | 0.00045 | 0 | <1.00e-15 | <4.50e-12 |
4 | MUTYH | mutY homolog (E. coli) | 118204 | 2 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0.0426 | 0.25 | 0.022 | 0 | <1.00e-15 | <4.50e-12 |
5 | SMAD4 | SMAD family member 4 | 117507 | 8 | 8 | 6 | 0 | 2 | 3 | 3 | 0 | 0 | 0 | 4.55e-11 | 0.16 | 0.14 | 0.14 | 1.64e-10 | 5.91e-07 |
6 | KIAA1804 | 165968 | 11 | 9 | 9 | 0 | 7 | 3 | 1 | 0 | 0 | 0 | 5.78e-09 | 0.025 | 0.011 | 0.011 | 1.50e-09 | 4.49e-06 | |
7 | FBXW7 | F-box and WD repeat domain containing 7 | 178296 | 12 | 9 | 10 | 0 | 6 | 2 | 2 | 0 | 2 | 0 | 7.15e-09 | 0.072 | 0.059 | 0.058 | 9.39e-09 | 2.42e-05 |
8 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 40434 | 5 | 5 | 4 | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 7.03e-08 | 0.012 | 0.42 | 0.023 | 3.44e-08 | 7.74e-05 |
9 | TCF7L2 | transcription factor 7-like 2 (T-cell specific, HMG-box) | 140095 | 7 | 7 | 7 | 1 | 2 | 3 | 0 | 0 | 2 | 0 | 1.17e-07 | 0.061 | 0.033 | 0.032 | 7.65e-08 | 0.000153 |
10 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 226803 | 7 | 7 | 7 | 1 | 1 | 3 | 3 | 0 | 0 | 0 | 2.94e-07 | 0.11 | 0.39 | 0.15 | 7.77e-07 | 0.00140 |
11 | OPCML | opioid binding protein/cell adhesion molecule-like | 78039 | 6 | 6 | 6 | 1 | 1 | 3 | 0 | 0 | 2 | 0 | 2.42e-07 | 0.47 | 0.47 | 0.55 | 2.23e-06 | 0.00366 |
12 | SMAD2 | SMAD family member 2 | 99636 | 5 | 5 | 5 | 0 | 0 | 3 | 1 | 0 | 1 | 0 | 1.42e-05 | 0.012 | 0.3 | 0.018 | 4.04e-06 | 0.00606 |
13 | SPATA8 | spermatogenesis associated 8 | 22770 | 3 | 3 | 3 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 4.44e-06 | 0.098 | 0.48 | 0.14 | 9.21e-06 | 0.0128 |
14 | ERBB2 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | 261623 | 4 | 4 | 2 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0.0238 | 0.000088 | 0.022 | 0.000049 | 1.70e-05 | 0.0219 |
15 | IL1RAPL2 | interleukin 1 receptor accessory protein-like 2 | 144969 | 5 | 5 | 4 | 2 | 2 | 1 | 0 | 0 | 2 | 0 | 1.40e-05 | 0.12 | 0.99 | 0.14 | 2.78e-05 | 0.0334 |
16 | KRTAP5-5 | keratin associated protein 5-5 | 38816 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 6.12e-05 | 0.08 | 0.0071 | 0.038 | 3.29e-05 | 0.0370 |
17 | MARCKSL1 | MARCKS-like 1 | 35451 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0.00123 | 0.0017 | 0.17 | 0.0032 | 5.28e-05 | 0.0560 |
18 | FAM123B | family with sequence similarity 123B | 229757 | 8 | 6 | 8 | 1 | 0 | 2 | 1 | 0 | 5 | 0 | 0.000105 | 0.043 | 0.65 | 0.098 | 0.000128 | 0.128 |
19 | ZIM3 | zinc finger, imprinted 3 | 99015 | 6 | 5 | 6 | 0 | 1 | 1 | 3 | 0 | 1 | 0 | 4.61e-05 | 0.44 | 0.096 | 0.25 | 0.000144 | 0.134 |
20 | PIK3R1 | phosphoinositide-3-kinase, regulatory subunit 1 (alpha) | 161759 | 5 | 4 | 5 | 0 | 2 | 0 | 0 | 0 | 1 | 2 | 0.000441 | 0.023 | 0.59 | 0.027 | 0.000149 | 0.134 |
21 | OSBPL6 | oxysterol binding protein-like 6 | 208311 | 5 | 5 | 5 | 0 | 1 | 2 | 0 | 2 | 0 | 0 | 0.000176 | 0.22 | 0.059 | 0.076 | 0.000164 | 0.140 |
22 | SGCB | sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) | 65136 | 4 | 4 | 4 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 3.82e-05 | 0.28 | 0.67 | 0.4 | 0.000182 | 0.149 |
23 | LIFR | leukemia inhibitory factor receptor alpha | 232360 | 5 | 5 | 5 | 2 | 0 | 2 | 1 | 1 | 1 | 0 | 0.000225 | 0.22 | 0.051 | 0.075 | 0.000202 | 0.158 |
24 | TLL2 | tolloid-like 2 | 211905 | 3 | 3 | 2 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 0.0753 | 0.00014 | 0.18 | 0.00027 | 0.000240 | 0.173 |
25 | CACNG7 | calcium channel, voltage-dependent, gamma subunit 7 | 58512 | 3 | 3 | 3 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0.000639 | 0.49 | 0.0036 | 0.032 | 0.000241 | 0.173 |
26 | EPYC | epiphycan | 68517 | 4 | 3 | 4 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0.000465 | 0.033 | 0.45 | 0.047 | 0.000257 | 0.178 |
27 | FAT4 | FAT tumor suppressor homolog 4 (Drosophila) | 1029673 | 17 | 10 | 17 | 5 | 5 | 8 | 3 | 0 | 1 | 0 | 0.000303 | 0.036 | 0.45 | 0.078 | 0.000275 | 0.184 |
28 | CCBP2 | chemokine binding protein 2 | 79971 | 5 | 5 | 5 | 0 | 1 | 2 | 2 | 0 | 0 | 0 | 3.51e-05 | 0.77 | 0.3 | 0.8 | 0.000320 | 0.199 |
29 | FBXO15 | F-box protein 15 | 92322 | 3 | 3 | 3 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0.00232 | 0.0045 | 0.28 | 0.012 | 0.000321 | 0.199 |
30 | CASP14 | caspase 14, apoptosis-related cysteine peptidase | 51957 | 5 | 4 | 4 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0.000125 | 0.14 | 0.68 | 0.24 | 0.000344 | 0.201 |
31 | HHEX | hematopoietically expressed homeobox | 31954 | 2 | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0.0283 | 0.0025 | 0.35 | 0.0011 | 0.000355 | 0.201 |
32 | CSMD3 | CUB and Sushi multiple domains 3 | 791430 | 11 | 9 | 11 | 6 | 2 | 4 | 2 | 2 | 1 | 0 | 8.66e-05 | 0.42 | 0.17 | 0.36 | 0.000357 | 0.201 |
33 | REEP2 | receptor accessory protein 2 | 53463 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0.0169 | 0.51 | 0.0015 | 0.002 | 0.000387 | 0.211 |
34 | ZNF395 | zinc finger protein 395 | 105838 | 2 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0.0356 | 0.00066 | 0.77 | 0.0011 | 0.000452 | 0.238 |
35 | SLITRK1 | SLIT and NTRK-like family, member 1 | 144555 | 6 | 5 | 6 | 0 | 2 | 1 | 2 | 0 | 1 | 0 | 0.000237 | 0.14 | 0.57 | 0.18 | 0.000462 | 0.238 |
In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.
rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q |
---|---|---|---|---|---|---|---|---|---|
1 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 38 | 51 | 37 | 3519 | 363199 | 1.6e-14 | 7.2e-11 |
2 | TP53 | tumor protein p53 | 45 | 823 | 45 | 56787 | 17987 | 1.7e-13 | 2.6e-10 |
3 | APC | adenomatous polyposis coli | 66 | 838 | 50 | 57822 | 1039 | 1.7e-13 | 2.6e-10 |
4 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 5 | 28 | 5 | 1932 | 5755 | 7.8e-12 | 8.8e-09 |
5 | FBXW7 | F-box and WD repeat domain containing 7 | 12 | 91 | 6 | 6279 | 329 | 2.3e-11 | 2.1e-08 |
6 | SMAD4 | SMAD family member 4 | 8 | 159 | 6 | 10971 | 39 | 6.4e-10 | 4.8e-07 |
7 | KRTAP5-5 | keratin associated protein 5-5 | 2 | 1 | 2 | 69 | 2 | 1.5e-07 | 0.0001 |
8 | ERBB2 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | 4 | 41 | 3 | 2829 | 6 | 2e-06 | 0.0011 |
9 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 7 | 184 | 4 | 12696 | 1382 | 4.3e-06 | 0.0022 |
10 | LRP1B | low density lipoprotein-related protein 1B (deleted in tumors) | 20 | 18 | 2 | 1242 | 2 | 5e-05 | 0.023 |
Note:
n - number of (nonsilent) mutations in this gene across the individual set.
cos = number of unique mutated sites in this gene in COSMIC
n_cos = overlap between n and cos.
N_cos = number of individuals times cos.
cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.
p = p-value for seeing the observed amount of overlap in this gene)
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
num | gene | desc | n | mindist | nmuts0 | nmuts3 | nmuts12 | npairs0 | npairs3 | npairs12 |
---|---|---|---|---|---|---|---|---|---|---|
3882 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 38 | 0 | 278 | 416 | 445 | 278 | 416 | 445 |
7563 | TP53 | tumor protein p53 | 45 | 0 | 37 | 61 | 105 | 37 | 61 | 105 |
393 | APC | adenomatous polyposis coli | 66 | 0 | 11 | 21 | 47 | 11 | 21 | 47 |
2623 | FBXW7 | F-box and WD repeat domain containing 7 | 12 | 0 | 6 | 6 | 6 | 6 | 6 | 6 |
4886 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 5 | 0 | 6 | 6 | 6 | 6 | 6 | 6 |
6854 | SMAD4 | SMAD family member 4 | 8 | 0 | 4 | 4 | 6 | 4 | 4 | 6 |
2368 | ERBB2 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) | 4 | 0 | 3 | 3 | 3 | 3 | 3 | 3 |
3792 | KIAA1804 | 11 | 0 | 2 | 6 | 7 | 2 | 6 | 7 | |
3475 | IL1RAPL2 | interleukin 1 receptor accessory protein-like 2 | 5 | 0 | 1 | 3 | 3 | 1 | 3 | 3 |
2089 | DNAH5 | dynein, axonemal, heavy chain 5 | 19 | 0 | 1 | 2 | 2 | 1 | 2 | 2 |
Note:
n - number of mutations in this gene in the individual set.
mindist - distance (in aa) between closest pair of mutations in this gene
npairs3 - how many pairs of mutations are within 3 aa of each other.
npairs12 - how many pairs of mutations are within 12 aa of each other.
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | HSA04310_WNT_SIGNALING_PATHWAY | Genes involved in Wnt signaling pathway | APC, APC2, AXIN1, AXIN2, BTRC, CACYBP, CAMK2A, CAMK2B, CAMK2D, CAMK2G, CCND1, CCND2, CCND3, CER1, CHD8, CHP, CREBBP, CSNK1A1, CSNK1A1L, CSNK1E, CSNK2A1, CSNK2A2, CSNK2B, CTBP1, CTBP2, CTNNB1, CTNNBIP1, CUL1, CXXC4, DAAM1, DAAM2, DKK1, DKK2, DKK4, DVL1, DVL2, DVL3, EP300, FBXW11, FOSL1, FRAT1, FRAT2, FZD1, FZD10, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9, GSK3B, JUN, LEF1, LOC652788, LRP5, LRP6, MAP3K7, MAPK10, MAPK8, MAPK9, MMP7, MYC, NFAT5, NFATC1, NFATC2, NFATC3, NFATC4, NKD1, NKD2, NLK, PLCB1, PLCB2, PLCB3, PLCB4, PORCN, PPARD, PPP2CA, PPP2CB, PPP2R1A, PPP2R1B, PPP2R2A, PPP2R2B, PPP2R2C, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2, PRICKLE1, PRICKLE2, PRKACA, PRKACB, PRKACG, PRKCA, PRKCB1, PRKCG, PRKX, PRKY, PSEN1, RAC1, RAC2, RAC3, RBX1, RHOA, ROCK1, ROCK2, RUVBL1, SENP2, SFRP1, SFRP2, SFRP4, SFRP5, SIAH1, SKP1, SMAD2, SMAD3, SMAD4, SOX17, TBL1X, TBL1XR1, TBL1Y, TCF7, TCF7L1, TCF7L2, TP53, VANGL1, VANGL2, WIF1, WNT1, WNT10A, WNT10B, WNT11, WNT16, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B | 144 | APC(66), AXIN1(1), AXIN2(2), BTRC(3), CACYBP(1), CAMK2D(1), CHD8(2), CREBBP(4), CTNNB1(4), CUL1(1), DAAM1(1), DAAM2(4), DKK1(2), DKK2(1), DKK4(3), DVL2(1), DVL3(2), EP300(2), FBXW11(1), FZD1(1), FZD10(2), FZD3(3), FZD4(1), FZD6(3), GSK3B(1), LRP6(7), MAP3K7(2), MAPK10(4), MAPK8(5), MAPK9(2), MMP7(2), NFATC1(1), NFATC2(2), NFATC3(1), NFATC4(1), PLCB3(1), PLCB4(1), PPARD(1), PPP2CB(2), PPP2R1B(1), PPP2R2B(2), PPP2R2C(1), PPP3CA(2), PPP3CB(1), PPP3CC(1), PRICKLE1(3), PRICKLE2(1), PRKACA(1), PRKACG(1), PRKCA(2), PRKCG(2), RBX1(1), RHOA(1), ROCK1(7), ROCK2(4), RUVBL1(2), SENP2(1), SFRP1(1), SFRP2(2), SFRP4(1), SMAD2(5), SMAD3(3), SMAD4(8), TBL1X(1), TBL1Y(1), TCF7(3), TCF7L2(7), TP53(45), WNT10B(1), WNT2(1), WNT2B(2), WNT6(1), WNT8A(1), WNT9B(1) | 16648987 | 263 | 68 | 234 | 35 | 68 | 67 | 33 | 3 | 74 | 18 | <1.00e-15 | <6.22e-14 |
2 | GSK3PATHWAY | Bacterial lipopolysaccharide activates AKT to promote the survival and activation of macrophages and inhibits Gsk3-beta to promote beta-catenin accumulation in the nucleus. | AKT1, APC, AXIN1, CCND1, CD14, CTNNB1, DVL1, FZD1, GJA1, GNAI1, GSK3B, IRAK1, LBP, LEF1, LY96, MYD88, NFKB1, PDPK1, PIK3CA, PIK3R1, PPP2CA, PRKR, RELA, TIRAP, TLR4, TOLLIP, WNT1 | 26 | APC(66), AXIN1(1), CTNNB1(4), FZD1(1), GJA1(4), GNAI1(1), GSK3B(1), MYD88(1), NFKB1(3), PIK3CA(7), PIK3R1(5), TLR4(3) | 3101261 | 97 | 60 | 87 | 4 | 12 | 15 | 10 | 0 | 40 | 20 | <1.00e-15 | <6.22e-14 |
3 | ST_JNK_MAPK_PATHWAY | JNKs are MAP kinases regulated by several levels of kinases (MAPKK, MAPKKK) and phosphorylate transcription factors and regulatory proteins. | AKT1, ATF2, CDC42, DLD, DUSP10, DUSP4, DUSP8, GAB1, GADD45A, GCK, IL1R1, JUN, MAP2K4, MAP2K5, MAP2K7, MAP3K1, MAP3K10, MAP3K11, MAP3K12, MAP3K13, MAP3K2, MAP3K3, MAP3K4, MAP3K5, MAP3K7, MAP3K7IP1, MAP3K7IP2, MAP3K9, MAPK10, MAPK7, MAPK8, MAPK9, MYEF2, NFATC3, NR2C2, PAPPA, SHC1, TP53, TRAF6, ZAK | 38 | ATF2(1), CDC42(1), DLD(1), DUSP10(1), GCK(1), IL1R1(1), MAP2K4(2), MAP2K5(2), MAP3K1(2), MAP3K10(1), MAP3K12(2), MAP3K13(1), MAP3K2(1), MAP3K3(1), MAP3K4(3), MAP3K5(1), MAP3K7(2), MAP3K9(2), MAPK10(4), MAPK8(5), MAPK9(2), NFATC3(1), PAPPA(5), TP53(45), ZAK(2) | 5206358 | 90 | 54 | 75 | 11 | 34 | 19 | 12 | 3 | 22 | 0 | <1.00e-15 | <6.22e-14 |
4 | G1PATHWAY | CDK4/6-cyclin D and CDK2-cyclin E phosphorylate Rb, which allows the transcription of genes needed for the G1/S cell cycle transition. | ABL1, ATM, ATR, CCNA1, CCND1, CCNE1, CDC2, CDC25A, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, DHFR, E2F1, GSK3B, HDAC1, MADH3, MADH4, RB1, SKP2, TFDP1, TGFB1, TGFB2, TGFB3, TP53 | 25 | ATM(10), ATR(4), CCNA1(2), CDK4(1), CDKN1B(2), DHFR(1), GSK3B(1), RB1(3), TGFB2(4), TP53(45) | 3112957 | 73 | 51 | 58 | 11 | 24 | 18 | 10 | 2 | 18 | 1 | <1.00e-15 | <6.22e-14 |
5 | P53PATHWAY | p53 induces cell cycle arrest or apoptosis under conditions of DNA damage. | APAF1, ATM, BAX, BCL2, CCND1, CCNE1, CDK2, CDK4, CDKN1A, E2F1, GADD45A, MDM2, PCNA, RB1, TIMP3, TP53 | 16 | APAF1(1), ATM(10), CDK4(1), PCNA(1), RB1(3), TIMP3(1), TP53(45) | 1905683 | 62 | 50 | 47 | 6 | 21 | 14 | 9 | 2 | 15 | 1 | <1.00e-15 | <6.22e-14 |
6 | ATRBRCAPATHWAY | BRCA1 and 2 block cell cycle progression in response to DNA damage and promote double-stranded break repair; mutations induce breast cancer susceptibility. | ATM, ATR, BRCA1, BRCA2, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, HUS1, MRE11A, NBS1, RAD1, RAD17, RAD50, RAD51, RAD9A, TP53, TREX1 | 21 | ATM(10), ATR(4), BRCA1(1), BRCA2(11), FANCA(2), FANCD2(4), FANCF(1), FANCG(2), MRE11A(5), RAD17(2), RAD50(6), TP53(45) | 4587794 | 93 | 49 | 78 | 7 | 27 | 31 | 16 | 2 | 16 | 1 | <1.00e-15 | <6.22e-14 |
7 | PMLPATHWAY | Ring-shaped PML nuclear bodies regulate transcription and are required co-activators in p53- and DAXX-mediated apoptosis. | CREBBP, DAXX, HRAS, PAX3, PML, PRAM-1, RARA, RB1, SIRT1, SP100, TNF, TNFRSF1A, TNFRSF1B, TNFRSF6, TNFSF6, TP53, UBL1 | 13 | CREBBP(4), DAXX(1), PAX3(2), PML(1), RB1(3), SIRT1(1), TP53(45) | 1965067 | 57 | 49 | 42 | 5 | 26 | 7 | 8 | 2 | 14 | 0 | <1.00e-15 | <6.22e-14 |
8 | SA_G1_AND_S_PHASES | Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. | ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 | 15 | CDK4(1), CDKN1B(2), PRB1(1), TP53(45) | 831472 | 49 | 48 | 34 | 2 | 20 | 6 | 6 | 2 | 15 | 0 | <1.00e-15 | <6.22e-14 |
9 | RNAPATHWAY | dsRNA-activated protein kinase phosphorylates elF2a, which generally inhibits translation, and activates NF-kB to provoke inflammation. | CHUK, DNAJC3, EIF2S1, EIF2S2, MAP3K14, NFKB1, NFKBIA, PRKR, RELA, TP53 | 9 | CHUK(2), MAP3K14(1), NFKB1(3), TP53(45) | 1059846 | 51 | 47 | 36 | 3 | 22 | 7 | 8 | 2 | 12 | 0 | <1.00e-15 | <6.22e-14 |
10 | APOPTOSIS_GENMAPP | APAF1, BAK1, BCL2L7P1, BAX, BCL2, BCL2L1, BID, BIRC2, BIRC3, BIRC4, CASP2, CASP3, CASP6, CASP7, CASP8, CASP9, CYCS, FADD, FAS, FASLG, GZMB, IKBKG, JUN, MAP2K4, MAP3K1, MAP3K14, MAPK10, MCL1, MDM2, MYC, NFKB1, NFKBIA, PARP1, PRF1, RELA, RIPK1, TNF, TNFRSF1A, TNFRSF1B, TNFSF10, TP53, TRADD, TRAF1, TRAF2 | 41 | APAF1(1), BIRC2(2), BIRC3(5), CASP3(1), CASP6(1), FAS(2), GZMB(1), MAP2K4(2), MAP3K1(2), MAP3K14(1), MAPK10(4), NFKB1(3), TP53(45), TRAF1(1) | 3868503 | 71 | 49 | 56 | 8 | 27 | 12 | 11 | 2 | 19 | 0 | 1.11e-15 | 6.22e-14 |
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ERBB4PATHWAY | ErbB4 (aka HER4) is a receptor tyrosine kinase that binds neuregulins as well as members of the EGF family, which also target EGF receptors. | ADAM17, ERBB4, NRG2, NRG3, PRKCA, PRKCB1, PSEN1 | 6 | ADAM17(1), ERBB4(5), NRG2(2), NRG3(4), PRKCA(2) | 933406 | 14 | 9 | 14 | 1 | 4 | 5 | 1 | 1 | 3 | 0 | 0.00089 | 0.24 |
2 | C21_STEROID_HORMONE_METABOLISM | AKR1C4, AKR1D1, CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP21A2, HSD11B1, HSD11B2, HSD3B1, HSD3B2 | 11 | AKR1C4(1), AKR1D1(1), CYP11A1(2), CYP11B1(4), CYP21A2(1), HSD3B1(1), HSD3B2(1) | 921900 | 11 | 10 | 11 | 2 | 3 | 5 | 1 | 0 | 2 | 0 | 0.0012 | 0.24 | |
3 | HSA00140_C21_STEROID_HORMONE_METABOLISM | Genes involved in C21-steroid hormone metabolism | AKR1C4, AKR1D1, CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP21A2, HSD11B1, HSD11B2, HSD3B1, HSD3B2 | 11 | AKR1C4(1), AKR1D1(1), CYP11A1(2), CYP11B1(4), CYP21A2(1), HSD3B1(1), HSD3B2(1) | 921900 | 11 | 10 | 11 | 2 | 3 | 5 | 1 | 0 | 2 | 0 | 0.0012 | 0.24 |
4 | HSA00240_PYRIMIDINE_METABOLISM | Genes involved in pyrimidine metabolism | AICDA, AK3, CAD, CANT1, CDA, CMPK, CTPS, CTPS2, DCK, DCTD, DHODH, DPYD, DPYS, DTYMK, DUT, ECGF1, ENTPD1, ENTPD3, ENTPD4, ENTPD5, ENTPD6, ENTPD8, ITPA, NME1, NME2, NME4, NME6, NME7, NP, NT5C, NT5C1A, NT5C1B, NT5C2, NT5C3, NT5E, NT5M, NUDT2, PNPT1, POLA1, POLA2, POLD1, POLD2, POLD3, POLD4, POLE, POLE2, POLE3, POLE4, POLR1A, POLR1B, POLR1C, POLR1D, POLR2A, POLR2B, POLR2C, POLR2D, POLR2E, POLR2F, POLR2G, POLR2H, POLR2I, POLR2J, POLR2K, POLR2L, POLR3A, POLR3B, POLR3G, POLR3GL, POLR3H, POLR3K, PRIM1, PRIM2, RFC5, RRM1, RRM2, RRM2B, TK1, TK2, TXNRD1, TXNRD2, TYMS, UCK1, UCK2, UMPS, UPB1, UPP1, UPP2, UPRT, ZNRD1 | 86 | AICDA(1), CAD(1), CTPS(1), DCK(1), DHODH(1), DPYD(6), DPYS(1), DTYMK(1), ENTPD5(1), ENTPD6(1), NME6(1), NME7(2), NT5C1B(1), NT5C2(1), NT5E(1), PNPT1(5), POLA1(3), POLE(4), POLE2(1), POLR1A(3), POLR1B(2), POLR2B(3), POLR2K(1), POLR3A(4), POLR3B(5), POLR3K(1), PRIM2(3), RFC5(1), RRM1(1), TK2(1), TXNRD1(1), TXNRD2(1), TYMS(1), UMPS(1), UPB1(2), UPP2(1), UPRT(1) | 8537733 | 67 | 28 | 65 | 15 | 18 | 26 | 10 | 0 | 13 | 0 | 0.0027 | 0.35 |
5 | HCMVPATHWAY | Cytomegalovirus activates MAP kinase pathways in the host cell, inducing transcription of viral genes. | AKT1, CREB1, MAP2K1, MAP2K2, MAP2K3, MAP2K6, MAP3K1, MAPK1, MAPK14, MAPK3, NFKB1, PIK3CA, PIK3R1, RB1, RELA, SP1 | 15 | MAP2K1(1), MAP2K2(1), MAP2K3(4), MAP2K6(1), MAP3K1(2), MAPK3(1), NFKB1(3), PIK3R1(5), RB1(3) | 1817823 | 21 | 10 | 21 | 3 | 7 | 4 | 4 | 1 | 3 | 2 | 0.0028 | 0.35 |
6 | CREMPATHWAY | The transcription factor CREM activates a post-meiotic transcriptional cascade culminating in spermatogenesis. | ADCY1, CREM, FHL5, FSHB, FSHR, GNAS, XPO1 | 7 | ADCY1(4), FHL5(3), FSHB(1), FSHR(1), XPO1(1) | 969112 | 10 | 9 | 10 | 4 | 4 | 1 | 3 | 1 | 1 | 0 | 0.0041 | 0.42 |
7 | PAR1PATHWAY | Activated extracellular thrombin cleaves and activates the G-protein coupled receptors PAR1 and PAR4, which activate platelets. | ADCY1, ARHA, ARHGEF1, F2, F2R, F2RL3, GNA12, GNA13, GNAI1, GNAQ, GNB1, GNGT1, MAP3K7, PIK3CA, PIK3R1, PLCB1, PPP1R12B, PRKCA, PRKCB1, PTK2B, ROCK1 | 18 | ADCY1(4), ARHGEF1(1), F2(1), GNAI1(1), GNAQ(1), GNGT1(1), MAP3K7(2), PIK3R1(5), PPP1R12B(4), PRKCA(2), ROCK1(7) | 2455051 | 29 | 13 | 29 | 7 | 8 | 7 | 5 | 0 | 7 | 2 | 0.0052 | 0.45 |
8 | GSPATHWAY | Activated G-protein coupled receptors stimulate cAMP production and thus activate protein kinase A, involved in a number of signal transduction pathways. | ADCY1, GNAS, GNB1, GNGT1, PRKACA, PRKAR1A | 6 | ADCY1(4), GNGT1(1), PRKACA(1), PRKAR1A(4) | 661717 | 10 | 8 | 10 | 1 | 3 | 4 | 1 | 0 | 2 | 0 | 0.0063 | 0.48 |
9 | HSA00472_D_ARGININE_AND_D_ORNITHINE_METABOLISM | Genes involved in D-arginine and D-ornithine metabolism | DAO | 1 | DAO(4) | 74796 | 4 | 3 | 4 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0.0084 | 0.54 |
10 | NEUROTRANSMITTERSPATHWAY | Biosynthesis of neurotransmitters | DBH, GAD1, HDC, PNMT, TH, TPH1 | 6 | DBH(1), GAD1(2), HDC(5), TPH1(2) | 608603 | 10 | 7 | 10 | 2 | 3 | 5 | 1 | 0 | 1 | 0 | 0.0087 | 0.54 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.